Your browser doesn't support javascript.
loading
Current status of precision medicine in pediatric oncology in Spain: a consensus report by the Spanish Society of Paediatric Haematology and Oncology (SEHOP).
Gargallo, P; Bautista, F; Juan-Ribelles, A; Izquierdo, E; Soriano, A; de Rojas, T; Escudero, A; Lavarino, C; Solano, P; Hladun, R; Rubio-San-Simón, A; Martínez-Romera, I; Calabria, I; Olaciregui, N G; Castañeda-Heredia, A; de Álava, E; Pérez-Martínez, A; Astigarraga, I; Patiño-García, A; Alonso, J; Fernández-Teijeiro, A; Cañete, A; Moreno, L.
Afiliación
  • Gargallo P; Research Institute Hospital La Fe, Valencia, Spain. pablogt28@gmail.com.
  • Bautista F; Oncology Department, Health in Code Group, Paterna, Valencia, Spain. pablogt28@gmail.com.
  • Juan-Ribelles A; Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain.
  • Izquierdo E; Pediatric Oncology and Hematology Unit, La Fe University Hospital, Valencia, Spain.
  • Soriano A; Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children's University Hospital Niño Jesús, Madrid, Spain.
  • de Rojas T; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Escudero A; Pediatric OncoGenomics Unit, Pediatric Hematology-Oncology Department, Children's University Hospital Niño Jesús, Madrid, Spain.
  • Lavarino C; Translational Research in Pediatric Oncology, Hematopoietic Stem Cell Transplantation, Cell Therapy, INGEMM-IdiPAZ, La Paz University Hospital, Madrid, Spain.
  • Solano P; Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
  • Hladun R; Department of Pediatric Oncology, Hospital Infantil Virgen del Rocio, Sevilla, Spain.
  • Rubio-San-Simón A; Group of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR)-Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
  • Martínez-Romera I; Vall d'Hebron University Hospital, Barcelona, Spain.
  • Calabria I; Clinical Trials Unit, Pediatric Hematology-Oncology Division, Hospital Universitario Niño Jesús, Madrid, Spain.
  • Olaciregui NG; Pediatric Hematology and Oncology Unit, Madrid Montepríncipe Hospital, Madrid, Spain.
  • Castañeda-Heredia A; Oncology Department, Health in Code Group, Paterna, Valencia, Spain.
  • de Álava E; Laboratory of Molecular Oncology, Hospital Sant Joan de Déu, Esplugues de Llobregat, Barcelona, Spain.
  • Pérez-Martínez A; Department of Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.
  • Astigarraga I; Institute of Biomedicine of Seville, Virgen del Rocío University Hospital/CSIC/University of Sevilla/CIBERONC, Sevilla, Spain.
  • Patiño-García A; Pediatric Hemato-Oncology Department, Hospital Universitario La Paz, Madrid, Spain.
  • Alonso J; Servicio de Pediatria, Bio Cruces Health Research Institute, Hospital Universitario Cruces, Barakaldo, Bizkaia, Spain.
  • Fernández-Teijeiro A; Departamento de Pediatria, Universidad del Pais Vasco UPV/EHU, Leioa, Spain.
  • Cañete A; Laboratory and Department of Pediatrics, University Clinic of Navarra and Solid Tumor Area, CIMA, IdiSNA, Pamplona, Spain.
  • Moreno L; Instituto de Investigación de Enfermedades Raras and U758 (CB06/07/1009), CIBERER, Instituto de Salud Carlos III, Unidad de Tumores Sólidos Infantiles, Madrid, Spain.
Clin Transl Oncol ; 24(5): 809-815, 2022 May.
Article en En | MEDLINE | ID: mdl-35152364
ABSTRACT
The study analyzes the current status of personalized medicine in pediatric oncology in Spain. It gathers national data on the tumor molecular studies and genomic sequencing carried out at diagnosis and at relapse, the centers that perform these studies, the technology used and the interpretation and clinical applicability of the results. Current challenges and future directions to achieve a coordinated national personalized medicine strategy in pediatric oncology are also discussed. Next generation sequencing-based (NGS) gene panels are the technology used in the majority of centers and financial limitations are the main reason for not incorporating these studies into routine care. Nowadays, the application of precision medicine in pediatric oncology is a reality in a great number of Spanish centers. However, its implementation is uneven and lacks standardization of protocols; therefore, national coordination to overcome the inequalities is required. Collaborative work within the Personalized Medicine Group of SEHOP is an adequate framework for encouraging a step forward in the effort to move precision medicine into the national healthcare system.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hematología / Neoplasias Tipo de estudio: Guideline Límite: Child / Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2022 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Hematología / Neoplasias Tipo de estudio: Guideline Límite: Child / Humans País/Región como asunto: Europa Idioma: En Revista: Clin Transl Oncol Año: 2022 Tipo del documento: Article País de afiliación: España